Plasma Ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients

Journal of Clinical Gastroenterology

Volumn 46, Issue 4, 2012, Pages 328-333

  De Rueda, Paloma Muñoz ^a,b   Ruiz Extremera, Angeles ^b,c   Candel, Jose M ^a   Quiles, Rosa ^a,b   Martín, Ana Belen ^a   Diago, Moises ^d   Andrade, Raul ^b,e   Navarro, Jose M ^f   Gila, Ana ^a,b   León, Josefa ^a,b   Carazo, Angel ^a   Quintero, Dolores ^a,b   Salmerón, Javier ^a,b  

^a Unidad de Ap Digestivo HU San Cecilio de Granada y   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Servicio de Pediatría H U San Cecilio de Granada   (Spain)

^d Servicio de Ap Digestivo de Hospital General de Valencia   (Spain)

^e Servicio de Ap Digestivo de Hospital   (Spain)

^f HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

anti HCV therapy; ribavirin dose; ribavirin levels; sustained virological response

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS;

EID: 84858862580     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318237123f     Document Type: Article

References (25)

1. Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet. 2003;362:2095-2100. (Pubitemid 38035201)
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958-965. (Pubitemid 32913521)
3. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype-1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroentrology. 2006;131: 1040-1048. (Pubitemid 44515099)
4. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132:103-112. (Pubitemid 46127673)
5. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-1838.
6. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839-1850.
7. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705-716.
8. Fried MW, ShiffmanML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
9. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology. 2008; 47:1453-1461. (Pubitemid 351702729)
10. Jen J, Laughlin M, Chung C, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2002;72:349-361. (Pubitemid 35178861)
11. Maynard M, Pradat P, Gagnieu MC, et al. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype-1 patients. Antivir Ther. 2008;13:607-611. (Pubitemid 352016724)
12. Tsubota A, Hirose Y, Izumi N, et al. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol. 2003;55:360-367. (Pubitemid 36535366)
13. Arase Y, Ikeda K, Tsubota A, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology. 2005; 48:138-144. (Pubitemid 41201504)
14. Baiocchi L, De Leonardis F, Delle Monache M, et al. Plasma/erythrocyte ribavirin X100 ratio as an indicator of sustained virological response in HCV denotype 1 patients with early virological response. Antivir Ther. 2010;15:633-639.
15. Caballero T, Pérez-Milena A, Masseroli M, et al. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. J Hepatol. 2001;34:740-747. (Pubitemid 32488790)
16. Larrat S, Stanke-Labesque F, Plages A, et al. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother. 2003;47:124-129. (Pubitemid 36070352)
17. Lindahl K, Schvarcz R, Bruchfeld A, et al. Evidence that plasma concentration rather than dose per kilogram body weight predict ribavirin-induced anemia. J Viral Hepat. 2004;11:84-87. (Pubitemid 38221622)
18. Inoue Y, Homma M, Matsuzaki Y, et al. Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res. 2006;34: 23-27. (Pubitemid 43091872)
19. Rendon A, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2005;39:401-405. (Pubitemid 41003783)
20. Morello J, Soriano V, Barreiro P, et al. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother. 2010;54:1647-1649.
21. Lopez-Cortes LF, Valera-Bestard B, Gutierrez-Valencia A, et al. Role of pegylated interferon-a-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients. Clin Pharmacol Ther. 2008;84:573-580.
22. Lindahl K, Stahle L, Bruchfeld A, et al. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology. 2005;41: 275-279. (Pubitemid 40165370)
23. Morello J, Cuenca L, Soriano V, et al. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. J Infect Dis. 2010;202:1185-1191.
24. Morello J, Rodríguez-Novoa S, Jiménez-Nácher I, et al. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother. 2008;62:1174-1180.
25. Crespo M, Pou L, Esteban JI, et al. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir Ther. 2007;12:1217-1223.